SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Liu who wrote (737)8/12/1999 1:16:00 AM
From: Walter Morton  Read Replies (2) of 2742
 
----Original Message-----
From: David Irving <david_irving@bioaust.com.au>

Date: Wednesday, August 11, 1999 10:29 PM
Subject: Re: PAI-2

Reply to: Re: PAI-2 Dear Walter,

Our PAI-2 program leader will provide you with the information that you require.

Thank you for your interest in our project which is, as you have determined, at a very exciting stage.

Regards,

David.

>Dr David O. Irving
>Head of Development
>Biotech Australia Pty Ltd
>28 Barcoo Street
>Roseville NSW 2069
>Australia
>
>Phone: +61 2 9928 8829
>Fax: +61 2 9928 8899
>E-mail: David_Irving@bioaust.com.au
>
>

Walter Morton wrote:
>Hi,
>
>How are the PAI-2 clinical trials coming along? Are you happy with the
>results so far?
>
>When do you expect the Phase III clinical trials to begin? What will be
>involved in the Phase III trials that is different for the Phase II
clinical
>trials.
>
>Thank you,
>
>Walter Morton
>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News